Cargando…

Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma

BACKGROUND: Although checkpoint blockades have become widely used, the immunological impact in cancer patients, especially those with oral cavity squamous cell carcinoma (OCSCC), has not been well studied. METHODS: The present study assessed the immunological impact of anti-PD-1 (nivolumab) treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Ying, Neskey, David M., Horton, Joshua D., Paulos, Chrystal M., Knochelmann, Hannah M., Armeson, Kent E., Young, M. Rita I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076935/ https://www.ncbi.nlm.nih.gov/pubmed/32183719 http://dx.doi.org/10.1186/s12885-020-06726-3

Ejemplares similares

Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma
por: Knochelmann, Hannah M., et al.
Publicado: (2021)

Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma
por: Liu, Sixue, et al.
Publicado: (2021)

Programmed death 1 (PD‐1) and ligand (PD‐L1) inhibitors in head and neck squamous cell carcinoma: A meta‐analysis
por: Levy, Dylan A., et al.
Publicado: (2022)

Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy
por: Rangel Rivera, Guillermo O., et al.
Publicado: (2021)

Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines
por: Dwyer, Connor J., et al.
Publicado: (2019)

CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
por: Knochelmann, Hannah M., et al.
Publicado: (2018)

Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8(+) T cells
por: Dwyer, Connor J., et al.
Publicado: (2020)

Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies
por: Knochelmann, Hannah M, et al.
Publicado: (2021)

Identification of human CD4(+) T cell populations with distinct antitumor activity
por: Nelson, Michelle H., et al.
Publicado: (2020)

B cells imprint adoptively transferred CD8(+) T cells with enhanced tumor immunity
por: Smith, Aubrey S, et al.
Publicado: (2022)

Harnessing the Microbiome to Enhance Cancer Immunotherapy
por: Nelson, Michelle H., et al.
Publicado: (2015)

Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition
por: Knochelmann, Hannah M., et al.
Publicado: (2022)

Overview of immunology of oral squamous cell carcinoma
por: Sathiyasekar, Anisha Cynthia, et al.
Publicado: (2016)

Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis
por: Paulos, Chrystal M, et al.
Publicado: (2006)

Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy
por: Bowers, Jacob S., et al.
Publicado: (2019)

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma
por: Vos, Joris L., et al.
Publicado: (2021)

Prognostic factors in squamous cell carcinoma of the oral cavity
por: Montoro, José Raphael de Moura Campos, et al.
Publicado: (2015)

Potential clinical implications of CD4(+)CD26(high) T cells for nivolumab treated melanoma patients
por: Galati, Domenico, et al.
Publicado: (2023)

Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma
por: Melo-Alvim, Cecília, et al.
Publicado: (2022)

Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer
por: Philips, Ramez, et al.
Publicado: (2021)

Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
por: Oliva, Marc, et al.
Publicado: (2021)

Cancer Immunology with a Focus on Understudied Cancers as Targets for Immunotherapy
por: Young, M. Rita I.
Publicado: (2017)

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
por: Reuss, Joshua E., et al.
Publicado: (2016)

Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
por: Lai, Fei Ya, et al.
Publicado: (2023)

Is it necessary to remove submandibular glands in squamous cell carcinomas of the oral cavity?
por: BASARAN, B., et al.
Publicado: (2013)

ASC contributes to metastasis of oral cavity squamous cell carcinoma
por: Wu, Chi-Sheng, et al.
Publicado: (2016)

Onychopathy Induced by Nivolumab: A Targeted Immunotherapy
por: Zahoor, Fatima, et al.
Publicado: (2022)

Frequency of HPV in oral cavity squamous cell carcinoma
por: de Abreu, Priscila Marinho, et al.
Publicado: (2018)

Oncogene Amplification in Squamous Cell Carcinoma of the Oral Cavity
por: Saranath, Dhananjaya, et al.
Publicado: (1989)

The Prevalence of HPV in Oral Cavity Squamous Cell Carcinoma
por: Katirachi, Seyed Keybud, et al.
Publicado: (2023)

Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China
por: Lin, Ying-tao, et al.
Publicado: (2022)

The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020
por: Yan, Flora, et al.
Publicado: (2020)

The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies
por: Neal, Lillian R., et al.
Publicado: (2017)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

Specimen oriented intraoperative margin assessment in oral cavity and oropharyngeal squamous cell carcinoma
por: Horwich, P., et al.
Publicado: (2021)

Bilateral Exudative Retinal Detachments Associated with Nivolumab Immunotherapy
por: Ajlan, Radwan S., et al.
Publicado: (2020)

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
por: Chiang, Ryan S, et al.
Publicado: (2022)

Outcomes of re-irradiation for oral cavity squamous cell carcinoma
por: Chen, Yen-Chao, et al.
Publicado: (2022)

Oral Cavity Squamous Cell Carcinoma: An Update of the Pharmacological Treatment
por: Imbesi Bellantoni, Martina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7be873ijl63v5i59ogfhbd8mhk